GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » Revenue

Scinopharm Taiwan (TPE:1789) Revenue : NT$3,493 Mil (TTM As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan Revenue?

Scinopharm Taiwan's revenue for the three months ended in Sep. 2024 was NT$724 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was NT$3,493 Mil. Scinopharm Taiwan's Revenue per Share for the three months ended in Sep. 2024 was NT$0.80. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was NT$4.25.

During the past 12 months, the average Revenue per Share Growth Rate of Scinopharm Taiwan was 9.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 1.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -0.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was -4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Scinopharm Taiwan's highest 3-Year average Revenue per Share Growth Rate was 6.10% per year. The lowest was -10.40% per year. And the median was -4.05% per year.


Scinopharm Taiwan Revenue Historical Data

The historical data trend for Scinopharm Taiwan's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan Revenue Chart

Scinopharm Taiwan Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,892.78 3,082.93 2,762.34 3,264.05 3,186.08

Scinopharm Taiwan Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 659.59 1,123.16 883.23 762.36 724.22

Competitive Comparison of Scinopharm Taiwan's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Revenue distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's Revenue falls into.



Scinopharm Taiwan Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3,493 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scinopharm Taiwan  (TPE:1789) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Scinopharm Taiwan Revenue Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinopharm Taiwan Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is primarily engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. Schinopharm also conducts consulting and technical services. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.

Scinopharm Taiwan Headlines

No Headlines